Benefits
Brain Health and Cognitive Support
Lion’s Mane may stimulate nerve growth factor (NGF) production, promoting neuron growth and repair. Studies suggest it could improve memory, focus, and cognitive function, The best-studied use is mild cognitive impairment, though the trials are small and largely from a single research group. Lion's mane is not a treatment for Alzheimer's or any other diagnosed disease.
Mood and Mental Health
Some research indicates it may reduce symptoms of anxiety and depression by modulating brain inflammation and supporting neural health, though human studies are limited.
Neuroprotection
In laboratory and animal studies, its antioxidant activity protected nerve cells from oxidative stress. Effects on age-related cognitive decline or nerve-injury recovery have not been demonstrated in human trials.
Immune Support
Lion's mane contains beta-glucans, which activate immune cells in laboratory studies. Whether oral lion's mane changes immune function or infection risk in people has not been tested in human trials.
Anti-Inflammatory Effects
In laboratory and animal studies, lion's mane compounds reduced inflammatory markers. This has not been shown to improve arthritis, gut, or other conditions in human trials.
Digestive Health
In laboratory and animal studies, lion's mane extracts slowed growth of H. pylori and protected the stomach lining. These findings have not been confirmed in human trials.
Cancer-Cell Laboratory Studies (No Human Evidence)
In test-tube studies, lion's mane compounds slowed the growth of some cancer cell lines. This is preliminary in-vitro work only. There are no human trials, and lion's mane is not a cancer treatment.
Mechanism of action
Antioxidant Activity
Scavenges free radicals (e.g., reactive oxygen species) by donating electrons, stabilizing them and preventing cellular damage. Enhances endogenous antioxidant systems (e.g., upregulates glutathione and superoxide dismutase).
Anti-Inflammatory Effects
Inhibits pro-inflammatory enzymes like cyclooxygenase (COX) and lipoxygenase (LOX), reducing prostaglandin and leukotriene production. Suppresses inflammatory signaling pathways (e.g., NF-κB) and cytokines (e.g., TNF-α, IL-6), decreasing systemic inflammation.
Immune Modulation
In laboratory studies, lion's mane compounds affected mast-cell histamine release and showed antiviral activity against some viruses. These are preclinical findings, not tested in people.
Cardiovascular Protection
In animal and laboratory studies, lion's mane reduced LDL oxidation and affected nitric oxide signaling. These cardiovascular effects have not been demonstrated in human trials.
Neuroprotection
Crosses the blood-brain barrier to reduce oxidative stress and inflammation in neural tissue. In laboratory models it reduced amyloid-beta aggregation. This has not been shown to affect Alzheimer's disease in people.
Clinical trials
Double-blind, placebo-controlled trial in Japan in 30 adults aged 50-80 with mild cognitive impairment receiving Lion's Mane (Hericium erinaceus) 1 g three times daily (3 g/day) vs placebo for 16 weeks. (Mori et al. 2009, Phytother Res)
30 adults aged 50-80 with MCI. 16-week intervention.
Lion's Mane group showed significantly improved cognitive function scores (Revised Hasegawa Dementia Scale) at 8, 12, 16 weeks vs placebo. After discontinuation, scores declined. Critical caveat: small trial (n=30), single research group; independent replication has been limited. The most-cited Lion's Mane cognitive trial is now 15+ years old without robust replication.
Randomized, double-blind, placebo-controlled pilot study at Northumbria University investigating acute and chronic (28-day) cognitive effects of Lion's Mane vs placebo in 41 healthy young adults. (Docherty et al. 2023, Nutrients)
41 healthy young adults.
Acute: modestly improved processing speed and reduced subjective stress at 60 min vs placebo. Chronic: smaller effects at 28 days. Effects in healthy young adults are modest at best.
Trial in 77 overweight/obese individuals (mean age 53) receiving 8 weeks of Lion's Mane vs placebo. (Vigna et al. 2019, Evid Based Complement Alternat Med)
77 overweight/obese adults. 8-week intervention.
Modest improvements in mood (depression/anxiety scores) and sleep quality vs placebo. Small effect sizes; novel population.
4-week randomized, double-blind, placebo-controlled study in 30 menopausal women receiving 2 g/day Lion's Mane vs placebo. (Nagano et al. 2010, Biomed Res)
30 menopausal women. 4-week intervention.
Modest reductions in depression/anxiety scores and 'indefinite physical complaints' vs placebo. Small trial; very short duration; novel application.
Randomized, double-blind, placebo-controlled trial giving Hericium erinaceus fruiting body (2.4 g/day) for 12 weeks to middle-aged and older adults, with cognitive function measured by MMSE, Benton visual retention, and paired-associate learning. (Saitsu et al. 2019, Biomed Res)
Middle-aged and older adults, 12-week intervention.
Only the MMSE showed a significant improvement vs placebo; the Benton and paired-associate tests did not. Small trial, 12 weeks, same Japanese research group as the other cognitive trials. The cognitive evidence base is much smaller than marketing implies.
Small pilot study in Japan testing 1 g/day Lion's Mane extract for 49 weeks in patients with mild Alzheimer's disease.
Small pilot of mild AD patients.
Modest signals. Critical caveat: very small pilot, no robust placebo control; cannot be considered AD treatment evidence. Modern AD landscape includes cholinesterase inhibitors, memantine, and lecanemab/donanemab — Lion's Mane has no established AD role.